$LLY

Zakrowski Donald A sold $2.4M of LLY

Zakrowski Donald A (SVP, Finance, & CAO) sold 2,000 shares of ELI LILLY & Co (LLY) at $1185.01 ($2.37M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zakrowski Donald A
Published Aug 11, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational, financial, or regulatory information about LLY.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it less actionable as a fundamental signal.

03

What to watch

The sale size ($2.37M) and remaining holdings (1,526 shares) matter for context, but the article provides no trend history or whether other insiders sold around the same time.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Eli Lilly & Co.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows LLY SVP, Finance and CAO Donald Zakrowski sold 2,000 shares on 2026-08-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact on LLY price; any effect is more sentiment-related than fundamental.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through; this is company-specific insider dealing without new sector catalysts.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider sales can still reflect personal liquidity needs or risk management, but it is not strong enough to infer deteriorating fundamentals from a single transaction.

Key entities

  • ELI LILLY & Co

    Subject of the Form 4 insider transaction disclosure.

  • Donald Zakrowski

    SVP, Finance and CAO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYHighAI 9/10

Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor

Eli Lilly (LLY) hit a record high, raising its 2026 revenue forecast to $91-$92B, lifting its market value to $1.1T. Macro investor Jordi Visser predicts Lilly will become the world's most valuable company due to steady healthcare spending and AI investment. Analysts expect Nvidia's (NVDA) earnings per share to quadruple in three years, making Lilly's potential surpass a significant challenge.

$LLYHighAI 9/10

Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?

Eli Lilly (LLY) stock rose 22% in October, driven by strong Q3 earnings, higher revenue guidance, and positive clinical trial results for retatrutide. Revenue increased 39% to $24.4B, with Mounjaro and Zepbound contributing significantly. Lilly raised 2026 revenue guidance to $91B-$92B. Goldman Sachs set a $1,413 price target. Novo Nordisk (NVO) faces competition from retatrutide, which outperformed Ozempic in a Phase 3 trial.

$LLYMedAI 8/10

Micron, Samsung and SK hynix shares stumble, but this ETF rallies instead of chip stocks

ETFs focused on global pharmaceutical companies, particularly those in obesity treatment, saw strong returns amid tech and semiconductor stock declines. Eli Lilly reported Q3 revenue of $24.4B, up 38.6% YoY, driven by obesity drugs Mounjaro and Zepbound. Novo Nordisk and other Big Pharma stocks also rose, benefiting from defensive characteristics and upcoming clinical trial announcements.

$LLYHighAI 9/10

Eli Lilly Posts Strong Quarterly Results and Hits Record High Stock Price

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by GLP-1 drugs Mounjaro and Zepbound. The company raised full-year revenue guidance to $91B-$92B but slightly lowered EPS guidance to $35-$36. Despite strong growth, valuation concerns arise as the stock trades at 45x earnings, with market expectations already priced in.